Month: March 2022

Sompo International Prepares Insurance Business for Expansion and Next Phase of Sustainable Profitable Growth

Written by Customer Service on March 8, 2022. Posted in Public Companies.

PEMBROKE, Bermuda, March 07, 2022 (GLOBE NEWSWIRE) — Sompo International Holdings Ltd., a leading global provider of commercial and consumer property and casualty (re)insurance, announced today a strategic reorganization of its Insurance business to best prepare the business for expansion and sustainable growth as a market leading insurance and reinsurance organization. This new structure will ensure a consistent market approach and improve the ease of doing business globally with Sompo while leveraging the underwriting acumen, market expertise, consistency of appetite and focus on customer service that the organization has always prioritized. The following changes will be made effective April 4th to better support Sompo International’s insurance organization through the next phase of growth:Michael Chang has been named Global...

Forian Inc. to Announce Fourth Quarter and Full Year 2021 Results on March 24, 2022

Written by Customer Service on March 8, 2022. Posted in Earnings Releases And Operating Results.

NEWTOWN, Pa., March 07, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – Forian Inc. (Nasdaq:FORA), a provider of software, data, and analytics-enabled services for the healthcare and cannabis industries, will announce its financial results for the fourth quarter and year ending on December 31, 2021 on Thursday, March 24, 2022 after the close of the market. The Company will host a conference call and webcast at 4:30 p.m. (ET) on March 24, 2022 to discuss the results. To access the conference call, from the US dial (855) 940-5323 or for international calls dial (929) 517-0423, and enter Conference ID 1275289. The webcast will be available live at https://edge.media-server.com/mmc/p/7q8gypu2. This information is also available on our website at www.forian.com/investors. The earnings release along with a replay of the call promptly following...

Anfield Energy Closes Final Tranche of Private Placement

Written by Customer Service on March 8, 2022. Posted in Public Companies.

VANCOUVER, British Columbia, March 07, 2022 (GLOBE NEWSWIRE) — Anfield Energy Inc. (TSX.V: AEC; OTCQB: ANLDF; FRANKFURT: 0AD) (“Anfield” or the “Company”) is pleased to announce that it has closed the final tranche of its non-brokered private placement. The final tranche, consisting of 71,920,520 units (each, a “Unit”) at a price of $0.085 per Unit, raised gross proceeds of $6,116,644. Each Unit consists of one common share and one share purchase warrant (each, a “Warrant”), with each Warrant entitling the holder to purchase an additional common share at a price of $0.13 until March 7, 2024. Red Cloud Securities Inc. acted as a finder with respect to the private placement. In connection with completion of the final tranche of the private placement, the Company has paid $361,899 and issued 4,245,631 Warrants to certain arms’-length...

Canacol Energy Ltd. To Announce Fourth Quarter and Fiscal Year 2021 Financial Results on Thursday, March 17, 2022; Hold Conference Call on Friday, March 18, 2022

Written by Customer Service on March 7, 2022. Posted in Public Companies.

CALGARY, Alberta, March 07, 2022 (GLOBE NEWSWIRE) — Canacol Energy Ltd. (“Canacol” or the “Corporation”) (TSX:CNE; OTCQX:CNNEF; BVC:CNEC) will announce its fourth quarter and fiscal year 2021 financial results on Thursday, March 17, 2022, after the market closure. Senior Management will hold a Conference Call to discuss results on Friday, March 18, 2022 at 8:00 a.m. MST / 10:00 a.m. ET. The conference call may be accessed by dial in or via webcast:Pre-register for the Conference Call: https://dpregister.com/sreg/10164458/f1e1ffd796Dial In Toll Free: 1-844-784-1724Participant International Dial In: 1-412-317-6716Canada Toll Free: 1-866-450-4696Colombia Toll Free: 01800-9-156803UK Toll Free: 08082389064Webcast link: https://services.choruscall.com/mediaframe/webcast.html?webcastid=q3DaATM8 All...

Standard Lithium to Participate in 34th Annual Roth Conference

Written by Customer Service on March 7, 2022. Posted in Public Companies.

VANCOUVER, British Columbia, March 07, 2022 (GLOBE NEWSWIRE) — Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV: SLI) (NYSE: SLI) (FRA: S5L), an innovative technology and lithium project development company, will participate in the 34th Annual Roth Conference on March 14-15, 2022. Event: 34th Annual Roth Conference, Dana Point, CA (In person 1:1s)Topic: One-on-one meetingsDate: March 14-15, 2022Time: Throughout the day Management will be hosting one-on-one meetings throughout the day on Monday and Tuesday, March 14-15. Interested investors should contact their Roth representative or Standard Lithium’s IR Team at standardlithium@lhai.com. About Standard Lithium Ltd. Standard Lithium is an innovative technology and lithium development company. The Company’s flagship project is located in southern Arkansas, where...

Ensurge Micropower ASA – Issuance of Shares in connection with Share Consolidation

Written by Customer Service on March 7, 2022. Posted in Public Companies.

Reference is made to the announcement by Ensurge Micropower ASA (the “Company”) on 24 February 2022, wherein the Extraordinary General Meeting approved, inter alia, an authorization to the board to issue shares in connection with the contemplated share consolidation in the Company. Pursuant to the board authorization, which may solely be used to make the total number of shares in the Company dividable by 9, the Company has consequently resolved to increase the Company’s share capital with NOK 0.44 from NOK 210,563,602.48 to NOK 210,563,602.92 by issuance of 4 new shares, each share having a par value of NOK 0.11, for a subscription price per share of NOK 0.11. Upon registration of this share capital increase, the Company’s share capital will be NOK 210,563,602.92 divided into 1,914,214,572 shares, each share having...

Acerus Announces Closing of Acquisition of Serenity Pharmaceuticals LLC and Acquisition of Global Rights to Noctiva™

Written by Customer Service on March 7, 2022. Posted in Mergers And Acquisitions.

Conference Call to be Held on March 9, 2022 at 8:30am ET to Discuss Transaction TORONTO, March 07, 2022 (GLOBE NEWSWIRE) — Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP; OTCQB:ASPCF) today announced the closing of its previously-announced acquisition of Serenity Pharmaceuticals LLC (“Serenity”), including the global rights to its Noctiva™ brand. Serenity, based in Miami, FL, is a specialty pharmaceutical company focused on developing therapies for diseases associated with voiding disorders and had previously been granted approval by the U.S. Food and Drug Administration (FDA) for its Noctiva™ (desmopressin acetate) nasal spray. Additional details of this transaction can be found in the Company’s filings in the US and Canada. Acerus will host an investor call to discuss the acquisition of Serenity on March...

VÍS: Viðskipti stjórnenda 07.03.2022

Written by Customer Service on March 7, 2022. Posted in Public Companies.

Viðskiptin eru liður í ráðstöfun kaupauka samkvæmt kaupaukakerfi VÍS vegna ársins 2021, sem gerir kröfu um að útborguðum kaupauka skuli ráðstafað til kaupa á hlutabréfum í félaginu með þriggja ára lágmarkseignarhaldstíma Sjá tilkynningar í meðfylgjandi viðhengjum:Attachments22.03.07 Seðlabanki Íslands_tilkynning um viðskipti_BJ22.03.07 Seðlabanki Íslands_tilkynning um viðskipti_GHH22.03.07 Seðlabanki Íslands_tilkynning um viðskipti_HB22.03.07 Seðlabanki Íslands_tilkynning um viðskipti_ARÍ22.03.07 Seðlabanki Íslands_tilkynning um viðskipti_HH22.03.02 Seðlabanki Íslands_tilkynning um viðskipti AG

Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results

Written by Customer Service on March 7, 2022. Posted in Earnings Releases And Operating Results.

SAN DIEGO, March 07, 2022 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today reported financial results for the three months and full year ended December 31, 2021 and provided an update on its corporate activities and product pipeline. “We made significant progress on several key initiatives during the fourth quarter,” said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara. “Of particular note is our December 2021 announcement of positive topline results from our pivotal ReSTORE Phase 3 clinical trial of rezafungin as a potential first-line treatment for candidemia and invasive candidiasis, which, combined with the data from the previously completed STRIVE...

Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2021 Financial Results

Written by Customer Service on March 7, 2022. Posted in Public Companies.

SAN DIEGO, March 07, 2022 (GLOBE NEWSWIRE) — Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report fourth quarter and full year 2021 financial results after the U.S. financial markets close on Thursday, March 10, 2022. Oncternal’s management will host a webcast at 2:00 p.m. PT (5:00 p.m. ET) to provide a comprehensive business update and discuss the Company’s financial results. The live webcast of the call will be available online at investor.oncternal.com and the call will be archived there for at least 30 days. About Oncternal TherapeuticsOncternal Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of patients with cancers...

Month: March 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals